September’s top stories: Iqarus UK training centre, J&J to buy Abbott Medical Optics

Iqarus intelligent health solutions opened a training centre in Hereford, UK, and Johnson & Johnson agreed to buy Abbott Medical Optics for $4.32bn. Medicaldevice-network.com wraps up the key headlines from September, 2016


Iqarus opens first responders training centre in UK

Iqarus intelligent health solutions opened a training centre in Hereford, UK to enhance the capability of first responders and healthcare professionals in addressing high-risk and high-pressure situations.

The new Immersive Training Centre has been designed using training technology to increase medical proficiency and the physical and mental resilience of the healthcare providers while they operate in remote and harsh environments.

Iqarus training and development executive director Ged Healy said: “At Iqarus, we train thousands of people every year, many of whom work in mission-critical environments where even minor incidents can have major consequences.

Johnson & Johnson to acquire Abbott Medical Optics for $4.32bn

Johnson & Johnson signed a definitive agreement to acquire Abbott Medical Optics (AMO), a wholly owned subsidiary of Abbott Laboratories, for $4.32bn in cash.

AMO posted sales of $1.1bn in 2015.

The acquisition will include ophthalmic products in three business segments including cataract surgery, laser refractive surgery and consumer eye health.

Royal Philips introduces patient experience solution on IBA proton therapy gantries

Royal Philips introduced its patient-centric Ambient Experience solution for Ion Beam Applications' (IBA) proton therapy gantries.

Phillips' Ambient Experience is an interactive healthcare environment, which uses modern technology and people-centric design to create a comfortable experience for both patients and staffs while ensuring improved workflows and operational efficiency.

The Ambient Experience will be incorporated on IBA's both proton therapy gantries which are the Proteus ONE and Proteus PLUS proton therapy solutions.

Natus agrees to acquire GN Otometrics for $145m

US-based medical device company Natus agreed with GN Store Nord to acquire GN Otometrics from GN Hearing for $145m.

Otometrics manufactures computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing and balance care professionals worldwide.

Generating annual revenue of about $110m, the company’s portfolio is characterised with sophisticated design technology catering to the hearing and balance assessment markets. Its global brands are Aurical, ICS and Madsen.

Shockwave Medical gets FDA approval for Lithoplasty System to treat calcified peripheral artery disease

Shockwave Medical secured clearance from the US Food and Drug Administration (FDA) for the Lithoplasty System intended for the treatment of calcified plaque in patients with peripheral artery disease (PAD).

PAD impacts nearly nine million people in the US. It blocks blood flow to the legs and feet, causing significant pain and limited mobility, and can lead to surgery or even amputation in severe cases.

Arterial calcification, due to plaque that hardens over time, is increasingly common as preventive care and disease management have enabled patients to live longer, thereby making vascular disease a chronic condition.

Tej Kohli Cornea Institute partners with LV Prasad Eye Institute to develop surgical treatment of SJS

The Tej Kohli Cornea Institute (TKCI) partnered with the India-based LV Prasad Eye Institute (LVPEI) to develop new treatments for Stevens-Johnson syndrome (SJS).

SJS is when the body displays an unusual reaction to commonly prescribed medications triggering symptoms like eruptions and blisters all over the body and mucous membrane of the mouth, eye and gut.

TKCI director Dr Pravin Krishna said: “SJS requires a gamut of specialised treatment options depending on the severity of the disease.

Bruker introduces new preclinical imaging systems at WMIC 2016

US-based medical device company Bruker introduced two new preclinical imaging systems at the World Molecular Imaging Congress (WMIC) 2016.

The new systems are designed for routine imaging with better performance and convenience, and to probe into causes, progression, as well as the diagnosis and treatment of a disease.

Bruker’s new SkyScan 1276 microCT (X-ray micro-Computed Tomography) features better resolution, speed, accessibility and other innovations to promote an improved in vivo scanning of small laboratory animals and of in-vitro biological samples in preclinical studies.

New device detects rare progressive lung disease by sniffing patient’s breath

Université Paris-Saclay adopted the Technion Israel Institute of Technology developed device for the diagnosis of Pulmonary Arterial Hypertension (PAH).

The device called the e-nose, is composed of gold nanoparticles coupled with chemical modules and can detect the rare progressive lung disease by analysing a patient’s breath.

It is expected to pave the way for an appropriate diagnosis of this rare form of high-blood pressure.

Mevion unveils pencil beam scanning technology at ASTRO 2016

US-based Mevion Medical Systems unveiled its pencil beam scanning Hyperscan with Adaptive Aperture at the 2016 ASTRO Annual Meeting in Boston, US.

The proton micro-multileaf collimator (mMLC) technology has been added to Mevion S250i with Hyperscan which had rendered the pencil beam scanning sharper and faster, delivering the intensity modulated proton therapy (IMPT).

Mevion's S250 has been designed based on the gantry-mounted proton accelerator and uses Mevion’s patented direct beam technology.

Teva collaborates with Intel to develop wearable device to help treat Huntington disease

Teva Pharmaceutical Industries collaborated with Intel Corporation to develop a wearable device and machine learning platform that can be used by patients suffering from Huntington disease (HD).

This platform will enable continuous monitoring and analysis of important symptoms that impact daily living, thereby helping to gain a better understanding of disease progression to improve treatment.

The collaboration will see deployment of the new technology platform in a sub-study within the ongoing Phase 2 Open-Pride HD Study.